Compounded GLP-1 and the FDA Shortage List: 2026 Update
Last updated: April 1, 2026
The FDA just sent warning letters to 30 telehealth companies in a single day — and if you’ve been relying on compounded semaglutide or tirzepatide to lose weight affordably, what happens next directly affects your wallet, your prescription, and your access to medication. The rules around compounded GLP-1 and the FDA changed fast in 2025, and 2026 is shaping up to be even more disruptive. Before you renew your next prescription or switch providers, you need to understand exactly where things stand right now.
Most people scanning this article want a yes-or-no answer. The truth is more complicated — and the details below could save you hundreds of dollars or protect you from a serious legal gray area.
Quick Answer
As of 2026, compounded GLP-1 medications like semaglutide and tirzepatide are no longer widely available through most pharmacies. The FDA resolved both drug shortages (semaglutide in February 2025, tirzepatide in late 2024), ended grace periods for compounding in May 2025, and launched aggressive enforcement in early 2026. Limited exceptions still exist for patients with specific medical needs, but mass compounding for general weight loss is now prohibited.
Key Takeaways
- 🚨 FDA enforcement is active in 2026: 30 warning letters were issued to telehealth companies on March 3, 2026, for illegal marketing of compounded GLP-1s [8]
- ✅ Semaglutide shortage officially resolved as of February 21, 2025 [1]
- ✅ Tirzepatide shortage resolved in late 2024 (though briefly remanded for litigation review) [3]
- ⛔ Grace periods ended May 2025: Pharmacies can no longer routinely compound copies of commercially available GLP-1s [3]
- ⚠️ Narrow exceptions remain: Compounded GLP-1s are still allowed for non-standard doses or documented medical needs that branded products can’t meet [3]
- 💊 Dulaglutide and liraglutide remain in shortage as of early 2026 [1]
- 🤝 Hims & Hers partnered with Novo Nordisk and agreed to stop most compounded GLP-1 advertising after the March 2026 warning letters [4]
- 💰 Affordable branded options exist — programs like TrumpRX offer discounted GLP-1 pricing for uninsured patients
What Is Compounded GLP-1 and Why Did the FDA Get Involved?
Compounded GLP-1 medications are custom-made versions of drugs like semaglutide (Ozempic, Wegovy) or tirzepatide (Mounjaro, Zepbound), prepared by licensed compounding pharmacies. They became popular during the 2022–2024 shortage period because they were significantly cheaper than branded versions — often $150–$300/month versus $900+ for brand-name options.
The FDA permits compounding under specific conditions, primarily when a drug is on the official shortage list. Once a shortage is resolved, that legal basis disappears.
Why the FDA cracked down:
- Both semaglutide and tirzepatide shortages were officially resolved by early 2025 [1]
- Compounding pharmacies continued producing these drugs well after the shortage ended
- Many telehealth platforms made misleading claims about compounded GLP-1 safety and equivalence to FDA-approved drugs [8]
- FDA Commissioner Makary publicly stated in 2026 that ending unlawful mass compounding of GLP-1s is a top priority this year [2]
For a broader look at all approved options, see our complete GLP-1 drugs list and 2026 medication guide.
What Does the 2026 FDA Shortage List Actually Say About Compounded GLP-1?
The FDA shortage list is the legal foundation for compounding. When a drug is listed, compounders can legally produce it. When it’s removed, they generally cannot.
Current shortage status (as of April 2026):
| Drug | Shortage Status | Compounding Permitted? |
|---|---|---|
| Semaglutide injection | Resolved (Feb 21, 2025) | No (grace period ended May 2025) |
| Tirzepatide injection | Resolved (late 2024) | No (grace period ended May 2025) |
| Dulaglutide injection | Still in shortage | Yes (with conditions) |
| Liraglutide injection | Still in shortage | Yes (with conditions) |
Sources: FDA.gov [1], GoodRx [3]
Because semaglutide and tirzepatide are no longer on the shortage list, the primary legal justification for mass compounding those drugs is gone. Dulaglutide and liraglutide remain in shortage, so compounding of those drugs may still be permitted under applicable rules [1].
Common mistake: Assuming that because your pharmacy still offers compounded semaglutide, it must be legal. Some pharmacies are operating in violation of current FDA policy. Buying from them puts you at risk of receiving an unregulated product with no quality guarantee.
How Compounded GLP-1 and the FDA Enforcement Changed in Early 2026
This is where things moved fast — and where most patients got caught off guard.
On February 6, 2026, the FDA announced its intent to take decisive action against non-FDA-approved compounded GLP-1 drugs, including restricting the active pharmaceutical ingredients (APIs) used to make them and combating misleading direct-to-consumer advertising [2][5].
Then on March 3, 2026, the FDA publicly released 30 warning letters targeting telehealth companies and online wellness clinics for making false or misleading claims about compounded GLP-1 medications [8][4].
What those warning letters covered:
- Claiming compounded semaglutide is “equivalent” to Ozempic or Wegovy
- Marketing compounded drugs as FDA-approved
- Failing to disclose risks associated with non-approved compounded products
- Operating outside the narrow legal exceptions for compounding
Days after the warning letters dropped, Novo Nordisk and Hims & Hers Health announced a strategic partnership. Under this deal, Hims will offer Novo Nordisk’s branded GLP-1 medications and cease most advertising of compounded alternatives [4]. This was a significant signal: even major telehealth platforms are pivoting away from compounded GLP-1s.
The FDA also signaled it will use inspection authority on API manufacturers and increase enforcement against imported APIs — cutting off the supply chain for compounding ingredients at the source [2].
For patients tracking affordable access, our guide to cheap weight loss injections and GLP-1 shots covers what’s still available legally.
Who Can Still Get Compounded GLP-1 Medications in 2026?
Compounded GLP-1s are not completely gone. Narrow, legitimate exceptions still exist — but they apply to a small subset of patients.
You may still qualify for a compounded GLP-1 if:
- You have a documented allergy to an inactive ingredient in the FDA-approved version (e.g., a specific preservative or filler)
- You need a non-standard dose that isn’t available in any commercially approved product
- Your prescriber documents a specific clinical need that cannot be met with an approved product [3]
- The drug you need remains on the shortage list (currently dulaglutide or liraglutide)
You do NOT qualify simply because:
- The branded version is too expensive
- You prefer a different delivery method
- A telehealth company advertises it as a “better” option
“Compounding cannot be used simply to create cheaper or slightly different versions of FDA-approved medications.” — FDA policy, as summarized by GoodRx [3]
Edge case: Some 503A compounding pharmacies (patient-specific) can still fill individual prescriptions with documented clinical justification. 503B outsourcing facilities (bulk compounders) face much stricter restrictions and cannot legally produce semaglutide or tirzepatide for general distribution in 2026.
What Are the Most Affordable Legal Alternatives to Compounded GLP-1s?
This is the question most readers actually need answered. Branded GLP-1s are expensive — but legal, affordable pathways do exist in 2026.
Option 1: TrumpRX Program The TrumpRX initiative offers significantly discounted pricing on branded GLP-1 medications for uninsured and underinsured Americans. See the full TrumpRX weight loss price breakdown for current Ozempic and Wegovy rates, or check TrumpRX eligibility requirements to see if you qualify.
Option 2: Manufacturer Savings Programs
- Novo Nordisk’s savings card for Wegovy can reduce costs for commercially insured patients
- Eli Lilly’s savings program for Zepbound offers similar discounts
Option 3: GLP-1 Direct Pay Programs Some clinics offer direct-pay GLP-1 programs that negotiate lower prices. Our best GLP-1 direct pay programs guide lists options starting under $200/month.
Option 4: Telehealth Platforms with Branded GLP-1s After the Hims/Novo Nordisk partnership, more telehealth platforms are shifting to branded medications. Compare options in our best affordable GLP-1 weight loss programs list.
Option 5: Insurance Appeals If your insurance denied coverage, it’s worth fighting. Our guide on how to appeal an insurance denial for semaglutide walks through the process step by step.
What Should You Do Right Now If You’re Currently on Compounded GLP-1?
If you’re currently using compounded semaglutide or tirzepatide, here’s a practical action plan:
Step 1: Don’t stop your medication abruptly. Talk to your prescriber before making any changes. Stopping GLP-1s suddenly can cause rapid weight regain.
Step 2: Ask your prescriber if you qualify for a documented exception. If you have a genuine clinical need (allergy, non-standard dose), your prescriber can document it and potentially continue compounded therapy legally.
Step 3: Explore branded alternatives with savings programs. Check semaglutide cost breakdowns and semaglutide without insurance options to find what’s realistic for your budget.
Step 4: Verify your pharmacy’s compliance. If a pharmacy is still offering compounded semaglutide or tirzepatide without a documented clinical exception, they may be operating illegally. This puts you at risk of receiving an unverified product.
Step 5: Consider oral GLP-1 options. Rybelsus (oral semaglutide) is FDA-approved and sometimes more accessible. See our oral GLP-1 for weight loss guide for a full comparison.
Compounded GLP-1 and the FDA: What to Expect for the Rest of 2026
Based on FDA Commissioner Makary’s public statements and the enforcement actions already taken, here’s what’s likely coming:
- More warning letters: The FDA has signaled continued enforcement against telehealth companies making misleading GLP-1 claims [2][7]
- API supply restrictions: The FDA is expected to use inspection authority on GLP-1 API manufacturers and crack down on imported APIs, making compounding ingredients harder to source [2]
- DOJ referrals: Some cases may be referred to the Department of Justice for criminal enforcement [9]
- Continued litigation: Some compounding pharmacies and patient advocates are challenging the FDA’s shortage determinations in court, which could create temporary exceptions [3]
- Possible new shortage listings: If branded GLP-1 supply tightens again (due to demand spikes or manufacturing issues), the FDA could relist drugs on the shortage list — reopening compounding access
The landscape is genuinely fluid. Bookmark this page and check back, because the rules could shift again before year-end.
FAQ: Compounded GLP-1 and the FDA in 2026
Q: Is compounded semaglutide still legal in 2026? Compounded semaglutide is no longer legal for routine dispensing. The shortage was resolved in February 2025, grace periods ended in May 2025, and the FDA is actively enforcing against pharmacies that continue mass compounding. Narrow exceptions exist for documented clinical needs. [1][3]
Q: Can I still get compounded tirzepatide? No, not routinely. Tirzepatide’s shortage was resolved in late 2024 and grace periods ended May 2025. The same narrow exceptions apply as with semaglutide. [3]
Q: What happens if I keep buying compounded GLP-1 from my current provider? You risk receiving a product that hasn’t been verified for potency, sterility, or safety. The pharmacy may also face FDA enforcement action, which could disrupt your supply without warning.
Q: Are there any GLP-1s still on the FDA shortage list? Yes. As of early 2026, dulaglutide injection and liraglutide injection remain in shortage, meaning compounding of those specific drugs may still be permitted under applicable conditions. [1]
Q: Why did Hims & Hers stop selling compounded GLP-1s? Following the March 3, 2026 FDA warning letters and a new partnership with Novo Nordisk, Hims & Hers agreed to cease most advertising and marketing of compounded GLP-1 alternatives and shift to branded medications instead. [4]
Q: What’s the cheapest legal GLP-1 option in 2026? The TrumpRX program and manufacturer savings cards are currently among the most affordable legal pathways. Some programs offer branded semaglutide starting around $149–$200/month for eligible patients. Check our cheapest GLP-1 medications guide for current pricing.
Q: Can a doctor still prescribe compounded GLP-1 for a specific patient? Yes, if the prescriber documents a specific medical need that cannot be met with an FDA-approved product — such as an allergy to an inactive ingredient or a required non-standard dose. This is a narrow exception, not a general workaround for cost. [3]
Q: Will the FDA eventually approve a generic semaglutide? Generic GLP-1s are not yet approved and are likely years away from market. Until then, branded medications with savings programs remain the primary affordable legal option.
Conclusion: What This Means for Your Weight Loss Plan
The era of cheap, widely available compounded GLP-1s is effectively over for most patients. The FDA resolved the key drug shortages, ended compounding grace periods in May 2025, and launched its most aggressive enforcement campaign yet in early 2026 — including 30 warning letters in a single day and a crackdown on API supply chains.
Your actionable next steps:
- Don’t panic — legal, affordable options exist through manufacturer programs, TrumpRX, and direct-pay clinics
- Talk to your doctor about whether you qualify for a legitimate compounding exception
- Compare branded GLP-1 costs using savings programs before assuming you can’t afford them
- Avoid pharmacies still advertising compounded semaglutide or tirzepatide without documented clinical justification
- Stay informed — this regulatory environment is changing monthly, and new developments could affect your access
The goal of losing weight affordably is still achievable in 2026. It just requires working within the legal framework that now exists — and knowing exactly where to look.
For a full comparison of what’s available right now, start with our best affordable GLP-1 weight loss programs and the complete semaglutide dose guide for weight loss.
References
[1] FDA Clarifies Policies for Compounders as National GLP-1 Supply Begins to Stabilize – https://www.fda.gov/drugs/drug-safety-and-availability/fda-clarifies-policies-compounders-national-glp-1-supply-begins-stabilize
[2] FDA’s Makary Declares Upcoming Crackdown on GLP-1 Claims and Importation – https://www.mcdermottplus.com/insights/fdas-makary-declares-upcoming-crackdown-on-glp-1-claims-importation/
[3] Compounded GLP-1 Going Away – https://www.goodrx.com/classes/glp-1-agonists/compounded-glp-1-going-away
[4] FDA Warning Letters, Hims, Novo Nordisk, and Compounded GLP-1 – https://www.frierlevitt.com/articles/fda-warning-letters-hims-novo-nordisk-compounded-glp1/
[5] FDA Intends to Take Action Against Non-FDA-Approved GLP-1 Drugs – https://www.fda.gov/news-events/press-announcements/fda-intends-take-action-against-non-fda-approved-glp-1-drugs
[6] FDA Ramps Up Crackdown on GLP-1 Drug Compounders with Fresh Batch of 30 Warning Letters – https://www.fiercepharma.com/pharma/fda-ramps-crackdown-glp-1-drug-compounders-fresh-batch-30-warning-letters
[7] FDA Threats of Escalating Enforcement on GLP-1 Compounding – https://www.polsinelli.com/publications/fda-threats-escalating-enforcement-glp-1-compounding
[8] FDA Warns 30 Telehealth Companies Against Illegal Marketing of Compounded GLP-1s – https://www.fda.gov/news-events/press-announcements/fda-warns-30-telehealth-companies-against-illegal-marketing-compounded-glp-1s
[9] Oral Semaglutide and the GLP-1 Compounding Reckoning: From Regulatory Ambiguity to FDA Enforcement, DOJ Referrals, and Novo Nordisk’s Case Against Hims and Hers – https://www.bipc.com/oral-semaglutide-and-the-glp-1-compounding-reckoning-from-regulatory-ambiguity-to-fda-enforcement,-doj-referrals,-and-novo-nordisk%E2%80%99s-case-against-hims-and-hers
With over 13 years of experience in holistic health blogging, I aim to help you navigate your wellness journey with honest insights, expert-backed advice, and a sprinkle of real-world practicality.
Certified Wellness Writer | Herbal Nutrition Advocate | Wellness Research Enthusiast
